Browsing Tag
obesity treatment
39 posts
How petrelintide’s tolerability profile could reshape patient adherence in obesity pharmacotherapy
Can petrelintide improve adherence in obesity treatment? Discover how Zealand Pharma’s therapy could reshape the weight-loss drug market.
EC backs higher-dose Wegovy as obesity competition intensifies
Novo Nordisk A/S wins EU approval for 7.2 mg Wegovy. Discover how this shifts obesity competition, reimbursement, and long-term strategy.
What’s next after Zepbound? Inside Eli Lilly and Company’s pipeline beyond GLP-1
Discover which drugs Eli Lilly and Company is betting on after Zepbound, including oral GLP-1 pills and next-generation incretins that could redefine the global obesity treatment market.
Will payers embrace premium weight loss? Inside the reimbursement risks of next-gen GLP-1s
As GLP‑1 weight‑loss drugs climb toward blockbuster status, insurers and payers face tough choices on coverage. Can premium weight‑loss therapies become mainstream?
Is dose escalation the new edge in the obesity drug war? Why GLP-1 rivals are raising the ceiling on efficacy
High-dose GLP-1 drugs like 7.2 mg Wegovy are redefining obesity treatment in 2025. Find out how dose escalation is shifting efficacy expectations.
Can 7.2 mg Wegovy redefine the weight loss standard in obesity treatment?
Novo Nordisk files for FDA approval of 7.2 mg Wegovy with fast-track priority review. See what this higher dose means for the future of obesity treatment.
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
Why investors are watching Ascletis Pharma’s monthly obesity shot as a potential GLP-1 disruptor
Ascletis Pharma reveals ASC36–ASC35 obesity combo with 51% greater weight loss vs tirzepatide. IND filing expected in 2026. Learn what’s next in its pipeline.
Can Camurus’ once-monthly semaglutide depot reshape the future of obesity and diabetes treatment?
Camurus reports positive Phase 1b results for CAM2056, a monthly semaglutide depot, showing 9.3% weight loss and strong A1c reduction. Read the full data.
Novo Nordisk taps Emcure Pharmaceuticals to launch Poviztra in India as second brand of Wegovy
Novo Nordisk partners with Emcure Pharmaceuticals to launch Poviztra, a second brand of Wegovy, in India. Discover how this could reshape obesity treatment access.